Biocon launches its inaugural US-based manufacturing plant in Cranbury.
On September 12, 2025, Biocon Limited, a global biopharmaceutical company from India, announced the inauguration of its first US manufacturing facility in Cranbury, New Jersey. The facility, acquired from Eywa Pharma Inc. in 2023, has undergone a $30 million...
Facilitates prompt heart transplantation services at Apollo Seshadripuram
In a groundbreaking achievement, Apollo Hospitals in Bengaluru, in collaboration with the Bangalore Metro Rail Corporation Limited (BMRCL) and the state health authority, Jeeva Sarthakathe (JSK), successfully transported a donated human heart through the city's Metro...
India’s Vaccine Development Gets Boost with Indigenous Efforts, AI-Powered ICMR, Gennova, and Zydus Led Initiatives
The Indian Council of Medical Research (ICMR) has been driving efforts to indigenize vaccine development in India, leveraging advanced technologies such as artificial intelligence (AI). This initiative aims to enhance the country's self-reliance in vaccine production...
Pharmaceutical and healthcare industries excel in the BT500 2025 rankings.
The Indian healthcare sector has experienced a significant surge in profit, with a 29% rise in profit after tax (PAT) in the fiscal year 2025. This makes it the second-fastest growing sector in the country, surpassed only by the non-ferrous metals sector. The...
Apollo has successfully performed more than 50 liver transplants covered by the Chief Minister’s insurance scheme
Apollo Hospitals in Chennai has successfully completed over 50 liver transplants under the Chief Minister's Comprehensive Health Insurance Scheme (CMCHIS). This achievement has benefited patients from underserved socio-economic groups across Tamil Nadu. The hospital...
Pfizer Vietnam, in partnership with Long Chau, aims to provide training for pharmacy and vaccination professionals.
Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres have signed a Memorandum of Understanding (MoU) to collaborate on enhancing the capabilities of thousands of healthcare professionals in Vietnam. The two-year partnership aims to improve healthcare quality by...
US FDA issues ‘Official Action Indicated’ status to Sun Pharma’s Halol facility due to recurring safety violations.
The US Food and Drug Administration (FDA) has flagged Sun Pharma's Halol plant in India with an "Official Action Indicated" (OAI) status. This decision comes after the plant was found to have repeated safety breaches. The OAI status is a serious warning from the FDA,...
Pfizer reports that the current season’s COVID vaccine increases immune responses by a factor of four.
Pfizer has announced that this season's COVID-19 vaccine shot has shown to boost immune responses fourfold. The company, along with its partner BioNTech, released the results of a Phase III trial for their COVID-19 vaccine, Comirnaty. The trial demonstrated a strong...
Pharmaceutical and healthcare industries excel in the BT500 2025 rankings.
The Indian healthcare sector has experienced a significant surge in profit, with a 29% rise in profit after tax (PAT) in the fiscal year 2025. This makes it the second-fastest growing sector in the country, surpassed only by the non-ferrous metals sector. The...
US FDA issues ‘Official Action Indicated’ status to Sun Pharma’s Halol facility due to recurring safety violations.
The US Food and Drug Administration (FDA) has flagged Sun Pharma's Halol plant in India with an "Official Action Indicated" (OAI) status. This decision comes after the plant was found to have repeated safety breaches. The OAI status is a serious warning from the FDA,...
Sun Pharma and Lupin are developing an anti-obesity oral medication to reduce costs and cater to those hesitant about injections.
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and...
Sun Pharma’s application for a bioequivalence and phase III trial waiver for its Sitagliptin, Glimepiride, and Metformin fixed-dose combination has been rejected by the CDSCO.
Sun Pharmaceutical Industries, a prominent pharmaceutical company, has faced a setback in its attempt to secure approval from the Central Drugs Standard Control Organisation (CDSCO) for a bioequivalence (BE) study and Phase III clinical trial waiver for its fixed-dose...
Prohance D by Sun Pharma empowers individuals with diabetes to maintain an active lifestyle.
Sun Pharmaceutical Industries Limited, India's leading pharmaceutical company, has launched a large-scale digital video campaign for Prohance D Diabetes Care, a nutritional supplement designed for individuals managing diabetes. The campaign, titled "Dekhta Hoon Nahi,...
Gujarat Emerges as a Thriving Pharmaceutical Hub in India
Gujarat is playing a vital role in India's pharmaceutical industry, driven by government initiatives and investment opportunities. The state is home to major pharmaceutical companies such as Sun Pharma, Zydus Cadila, and Intas Pharmaceuticals, contributing...
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce...
CDSCO Panel Approves Sun Pharma’s Phase IV Clinical Trial for Dual Release Pantoprazole in Treating Gastroesophageal Reflux Disease (GERD)
Sun Pharma, a leading pharmaceutical company, has announced that its Phase IV study on dual release pantoprazole for the treatment of Gastroesophageal Reflux Disease (GERD) has received acceptance from the Central Drugs Standard Control Organization (CDSCO) panel....
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk's blockbuster weight-loss drug, semaglutide, which is sold...
Natco Pharma files lawsuit against Novo Nordisk in Delhi courts regarding intellectual property dispute over Semaglutide.
Natco Pharma, an Indian pharmaceutical company, has filed a lawsuit against Novo Nordisk, a Danish multinational pharmaceutical company, in a Delhi court over intellectual property rights related to semaglutide. Semaglutide is a medication used to treat type 2...
Natco Pharma names TC Mallikarjun as its new Vice President.
Natco Pharma, a leading pharmaceutical company, has announced the appointment of TC Mallikarjun as Vice President - Quality Control (QC) at its Kothur Pharma Division. This appointment is a significant development for the company, as it continues to strengthen its...
Access to the Request Has Been Denied
It appears that you have encountered an error while trying to access the website www.tipranks.com. The error message indicates that your request was blocked by Link11 Web Application Security, which is a security system designed to protect websites from malicious...
US FDA issues single Form 483 observation to NATCO Pharma’s Hyderabad plant following audit.
NATCO Pharma, a leading pharmaceutical company based in Hyderabad, India, has received a positive outcome from a recent US Food and Drug Administration (US FDA) audit. The company's plant, located in Hyderabad, was inspected by the US FDA, and the audit resulted in...
Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company's quarterly...
Divis Laboratories signs long-term manufacturing and supply pact with international pharmaceutical company.
Divis Laboratories has secured a long-term manufacturing and supply agreement with a global pharmaceutical company. Under the terms of the agreement, Divis will manufacture and supply advanced intermediates to the pharma company, with the details of the commercial...
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic...
Biocon launches its inaugural US-based manufacturing plant in Cranbury.
On September 12, 2025, Biocon Limited, a global biopharmaceutical company from India, announced the inauguration of its first US manufacturing facility in Cranbury, New Jersey. The facility, acquired from Eywa Pharma Inc. in 2023, has undergone a $30 million...
Facilitates prompt heart transplantation services at Apollo Seshadripuram
In a groundbreaking achievement, Apollo Hospitals in Bengaluru, in collaboration with the Bangalore Metro Rail Corporation Limited (BMRCL) and the state health authority, Jeeva Sarthakathe (JSK), successfully transported a donated human heart through the city's Metro...
India’s Vaccine Development Gets Boost with Indigenous Efforts, AI-Powered ICMR, Gennova, and Zydus Led Initiatives
The Indian Council of Medical Research (ICMR) has been driving efforts to indigenize vaccine development in India, leveraging advanced technologies such as artificial intelligence (AI). This initiative aims to enhance the country's self-reliance in vaccine production...
Pharmaceutical and healthcare industries excel in the BT500 2025 rankings.
The Indian healthcare sector has experienced a significant surge in profit, with a 29% rise in profit after tax (PAT) in the fiscal year 2025. This makes it the second-fastest growing sector in the country, surpassed only by the non-ferrous metals sector. The...
Apollo has successfully performed more than 50 liver transplants covered by the Chief Minister’s insurance scheme
Apollo Hospitals in Chennai has successfully completed over 50 liver transplants under the Chief Minister's Comprehensive Health Insurance Scheme (CMCHIS). This achievement has benefited patients from underserved socio-economic groups across Tamil Nadu. The hospital...
Pfizer Vietnam, in partnership with Long Chau, aims to provide training for pharmacy and vaccination professionals.
Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres have signed a Memorandum of Understanding (MoU) to collaborate on enhancing the capabilities of thousands of healthcare professionals in Vietnam. The two-year partnership aims to improve healthcare quality by...
US FDA issues ‘Official Action Indicated’ status to Sun Pharma’s Halol facility due to recurring safety violations.
The US Food and Drug Administration (FDA) has flagged Sun Pharma's Halol plant in India with an "Official Action Indicated" (OAI) status. This decision comes after the plant was found to have repeated safety breaches. The OAI status is a serious warning from the FDA,...
Pfizer reports that the current season’s COVID vaccine increases immune responses by a factor of four.
Pfizer has announced that this season's COVID-19 vaccine shot has shown to boost immune responses fourfold. The company, along with its partner BioNTech, released the results of a Phase III trial for their COVID-19 vaccine, Comirnaty. The trial demonstrated a strong...
Sun Pharma and Lupin are developing an anti-obesity oral medication to reduce costs and cater to those hesitant about injections.
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and...
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce...
Pharma’s quest for expansion: Reaching out to the consumer’s doorstep
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and...
Cipla’s CEO responds to tariff threats, highlighting the company’s diversified business model as a key strength.
Cipla, a leading pharmaceutical company, is confident in its ability to withstand the potential impact of tariff threats on its business. In a recent interview, Cipla's CEO, Umang Vohra, emphasized that the company has "one of the most well-diversified models" in the...
Global Digoxin Industry Analysis: An In-Depth Report Featuring Key Players Such as Pfizer, Novartis, and Mylan
The Global Digoxin Market study, recently introduced by HTF MI, provides a comprehensive overview of the product and industry scope, as well as an in-depth analysis of the market outlook and status from 2025 to 2031. The market is segmented by key regions, including...
Lupin Splits Off Its Consumer Healthcare Business to Form Independent Company
Lupin, a leading pharmaceutical company, has created a new subsidiary called LupinLife Consumer Healthcare Ltd to house its consumer healthcare business. This move is in line with a growing trend among pharmaceutical companies, both in India and globally, to separate...
The US Food and Drug Administration has issued a single observation for Cipla’s Bommasandra manufacturing facility.
The US Food and Drug Administration (USFDA) has issued a single observation for Cipla's Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility...
Amit Patel has been promoted to lead Consumer Marketing Excellence as its new Head.
Amit Patel has been promoted to Head of Consumer Marketing Excellence at Cipla India, a leading pharmaceutical company. In his new role, Patel will be responsible for driving consumer marketing across various therapeutic areas, with a focus on building patient-centric...
Facilitates prompt heart transplantation services at Apollo Seshadripuram
In a groundbreaking achievement, Apollo Hospitals in Bengaluru, in collaboration with the Bangalore Metro Rail Corporation Limited (BMRCL) and the state health authority, Jeeva Sarthakathe (JSK), successfully transported a donated human heart through the city's Metro...
Pharmaceutical and healthcare industries excel in the BT500 2025 rankings.
The Indian healthcare sector has experienced a significant surge in profit, with a 29% rise in profit after tax (PAT) in the fiscal year 2025. This makes it the second-fastest growing sector in the country, surpassed only by the non-ferrous metals sector. The...
Apollo has successfully performed more than 50 liver transplants covered by the Chief Minister’s insurance scheme
Apollo Hospitals in Chennai has successfully completed over 50 liver transplants under the Chief Minister's Comprehensive Health Insurance Scheme (CMCHIS). This achievement has benefited patients from underserved socio-economic groups across Tamil Nadu. The hospital...
Quote from Ms. Suneeta Reddy Regarding the Latest GST Update | Apollo Hospitals
The recent Goods and Services Tax (GST) rationalization has been well-received, particularly in the context of the healthcare sector. This move is seen as a complementary measure to the tax cuts and 100% Foreign Direct Investment (FDI) in insurance announced in the...
Hospitals are experiencing a significant change in their revenue streams, with oncology emerging as the most lucrative department.
India's top hospital chains, including Max Healthcare, Apollo Hospitals, and Fortis Healthcare, are experiencing a significant shift in their revenue mix, with oncology emerging as the fastest-growing and most profitable specialty. Oncology, once a niche segment, is...
Immersion ceremony of Lord Ganesh and food donation completed at Apollo Hospital premises.
On September 7, 2025, in Hyderabad, Telangana, a significant event took place at Apollo Hospitals, located in Jubilee Hills. An 8-foot tall Ganesh idol was installed within the hospital premises, marking the beginning of a festive period. The idol was worshipped with...
Apollo Hospitals achieves success – News Today
In a significant medical achievement, Apollo Hospitals in Chennai has successfully performed India's first implantation of the Edwards SAPIEN 3 Ultra RESILIA transcatheter aortic valve (TAVI) on a 70-year-old patient. The patient, who suffered from severe aortic...
Apollo Hospitals Hyderabad celebrates 37 years of excellence, with Sangita Reddy and Tejesvi Rao Veerepalli looking back on a legacy built on innovative healthcare and unwavering trust.
Apollo Hospitals in Hyderabad recently celebrated its 37th anniversary, marking a significant milestone in its journey as a pioneering healthcare institution in India. The hospital was among the first private healthcare institutions in the country to provide...
Pfizer Vietnam, in partnership with Long Chau, aims to provide training for pharmacy and vaccination professionals.
Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres have signed a Memorandum of Understanding (MoU) to collaborate on enhancing the capabilities of thousands of healthcare professionals in Vietnam. The two-year partnership aims to improve healthcare quality by...
Pfizer reports that the current season’s COVID vaccine increases immune responses by a factor of four.
Pfizer has announced that this season's COVID-19 vaccine shot has shown to boost immune responses fourfold. The company, along with its partner BioNTech, released the results of a Phase III trial for their COVID-19 vaccine, Comirnaty. The trial demonstrated a strong...
Key pharmaceutical marketing updates for Tuesday, September 9, 2025
Several recent developments in the pharmaceutical industry have shown promise and potential for growth. Pfizer reported positive Phase 3 results for its COVID-19 vaccine in adults, particularly in those aged 65 and older, demonstrating an improved immune response....
Appeals court upholds former Pfizer employee’s guilty verdict for insider trading
A former Pfizer Inc. statistician has had his insider trading conviction affirmed by the Second Circuit. The individual was found guilty of making $272,000 in options trades using nonpublic information about the success of trials for the COVID-19 therapy drug...
Pfizer requests FDA approval for COVID-19 vaccine in children aged 5 to 11.
Pfizer has submitted an application to the US Food and Drug Administration (FDA) to approve the use of its COVID-19 vaccine in children aged 5-11. This age group is currently not eligible for the vaccine, which is only authorized for individuals 12 years and older....
Biggest Global Pharma Firms of 2025: Ranking the Top 5
The pharmaceutical industry is a vital sector that produces life-saving medicines, vaccines, and treatments that improve global health. The top five largest pharmaceutical companies in the world, as of 2025, are Pfizer, Johnson & Johnson, AbbVie, Merck & Co., and...
Does Enanta’s Lawsuit and PADCEV Trial’s Positive Outcomes Alter Pfizer’s (PFE) Investment Storyline?
Pfizer, a leading pharmaceutical company, is facing a crucial period as it navigates through patent litigation and promising cancer trial results. Enanta Pharmaceuticals has initiated a lawsuit against Pfizer in the European Unified Patent Court, alleging infringement...
PFE transformation as a market catalyst fuels Institutional Tactics with a Liquidity Pulse, revolutionizing asset management strategies.
The key findings for Pfizer Inc. (NYSE: PFE) indicate a strong sentiment in the near and mid-term, but a weak long-term outlook. The analysis reveals no clear price positioning signal, but the upside opportunity looks excellent as long as the converted support holds....
Fortis introduces specialized orthopaedic and sports injury outpatient department in Srinagar
Fortis Healthcare has launched a monthly Orthopaedics and Sports Injury Outpatient Department (OPD) in Srinagar, aimed at providing specialized musculoskeletal and sports medicine care to residents. The OPD will be led by Dr. Tapish Shukla, an Associate Consultant in...
Hospitals are experiencing a significant change in their revenue streams, with oncology emerging as the most lucrative department.
India's top hospital chains, including Max Healthcare, Apollo Hospitals, and Fortis Healthcare, are experiencing a significant shift in their revenue mix, with oncology emerging as the fastest-growing and most profitable specialty. Oncology, once a niche segment, is...
Punjab’s Chief Minister is exhibiting signs of improvement while being closely monitored at Fortis Hospital.
Punjab Chief Minister Bhagwant Mann was admitted to Fortis Hospital in Mohali on Friday evening due to exhaustion and a low heart rate. The 51-year-old leader has been showing improvement, with stable vital signs and gradually improving blood parameters, according to...
Punjab Chief Minister Bhagwant Mann’s condition worsens, hospitalized at Fortis Mohali
Punjab Chief Minister Bhagwant Mann has been admitted to Fortis Hospital in Mohali due to health concerns. According to reports, Mann complained of exhaustion and a low heart rate, prompting his hospitalization. The news has led to the postponement of a scheduled...
Fortis Hospital in Mohali hosts the zonal finals of ‘PSYCH-ED 2025’
Fortis Hospital, Mohali, recently hosted the zonal finals of the 8th edition of its national psychology quiz program, "PSYCH-ED, 2025". The event saw participation from over 900 schools across India, with more than 12,000 students from 190+ cities taking part in the...
Fortis acquires Shrimann hospital in a massive Rs 462 crore deal
Fortis Healthcare has expanded its presence in Punjab by acquiring the 228-bed Shrimann Superspecialty Hospital for a consideration of Rs 462 crore. This marks the fifth hospital of Fortis in Punjab, with existing hospitals in Ludhiana, Mohali, and Amritsar. The...
Fortis Hospital ordered to compensate Rs 50 lakh for medical negligence
The District Consumer Disputes Redressal Commission in Chandigarh has held Fortis Hospital in Mohali and one of its doctors guilty of medical negligence. The commission has ordered the hospital to pay a compensation of Rs 50 lakh along with 9% interest per annum to...
Fortis and Agilus Enhance Genomic Testing Capabilities with Additional Genexus System, Accelerating Cancer Diagnosis.
Fortis and Agilus have partnered to enhance genomic testing capabilities with the installation of a second Genexus system. This move is expected to significantly improve the speed and accuracy of cancer diagnosis. The Genexus system is a next-generation sequencing...